A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

Leuk Lymphoma. 2016 Sep;57(9):2212-5. doi: 10.3109/10428194.2015.1129536. Epub 2016 Jan 14.

Authors

Affiliations

¹ a Division of Hematology, Department of Internal Medicine , The Ohio State University , Columbus , OH , USA ;
² b Comprehensive Cancer Center, The Ohio State University , Columbus , OH , USA ;
³ c Division of Pharmaceutics , College of Pharmacy, The Ohio State University , Columbus , OH , USA ;
⁴ d Division of Medicinal Chemistry , College of Pharmacy, The Ohio State University , Columbus , OH , USA.

No abstract available

Publication types

Clinical Trial, Phase I
Letter

MeSH terms

Aged
Benzoquinones / administration & dosage*
Benzoquinones / adverse effects
Benzoquinones / pharmacokinetics
Dose-Response Relationship, Drug
Female
HSP90 Heat-Shock Proteins / antagonists & inhibitors
Humans
Injections, Intravenous
Lactams, Macrocyclic / administration & dosage*
Lactams, Macrocyclic / adverse effects
Lactams, Macrocyclic / pharmacokinetics
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Male
Maximum Tolerated Dose
Middle Aged
Recurrence

Substances

Benzoquinones
HSP90 Heat-Shock Proteins
Lactams, Macrocyclic
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin

Grants and funding